The genetic basis of inhibitor development in haemophilia A
- 1 July 1998
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 4 (4), 543-545
- https://doi.org/10.1046/j.1365-2516.1998.440543.x
Abstract
Summary. Inhibitor development is now the main complication of replacement therapy in haemophilia A. Given that most severely affected patients make no detectable factor VIII, it is perhaps surprising that only ˜30% actually mount an immune response to factor VIII as a foreign antigen. Those that do mostly have major factor VIII gene lesions. The association of HLA genotype with inhibitors in patients with identical mutations is weak. Environmental factors may be more important than genetic in antibody response to factor VIII.Keywords
This publication has 9 references indexed in Scilit:
- HLA Genotype of Patients with Severe Haemophilia A due to Intron 22 Inversion with and without Inhibitors of Factor VIIIThrombosis and Haemostasis, 1997
- HLA Class II Profile: A Weak Determinant of Factor VIII Inhibitor Development in Severe Haemophilia AThrombosis and Haemostasis, 1997
- Absence of Inhibitors in Previously Untreated Patients with Severe Haemophilia A after Exposure to a Single Intermediate Purity Factor VIII ProductThrombosis and Haemostasis, 1997
- Nonsense Mutations Inhibit RNA Splicing in a Cell-Free System: Recognition of Mutant Codon Is Independent of Protein SynthesisCell, 1996
- Haemophilia A: Mutation Type Determines Risk of Inhibitor FormationThrombosis and Haemostasis, 1995
- Analyis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patientsHuman Molecular Genetics, 1993